|
|
Blood, Vol. 108, Issue 6, 1965-1971, September 15, 2006
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
Blood Teachey et al.
108: 1965
Supplemental materials for: Teachey et al
Files in this Data Supplement:
- Figure S1. Ultrasound accurately estimates organ volume (JPG, 57.7 KB)
-
In order to ensure ultrasound measurements reflected actual measurements, we compared spleen area from CBA-lprcg mice at sacrifice calculated as length x width by caliper to area calculated on Vevo 660 ultrasound (S1A). Linear regression analysis demonstrated a statistically significant correlation. We also compared number of cells in spleen (SIB) and lymph node (SIC) to Vevo 660 calculated sizes (volume for lymph node and area for spleen) and linear regression analysis demonstrated a statistically significant correlation.
- Figure S2. Rapamycin is superior to mycophenolate mofetil (MMF) (JPG, 53 KB)
-
CBA-lprcg mice were randomizd to treatment with rapamycin, MMF, or control. Serial ultrasounds were performed every 2 weeks to document splenic area in mm2. Rapamycin treated mice showed a statistically significant (p = 0.02) decrease in splenic area after 6 weeks of treatment when compared to MMF treated mice (S2A). Retro-orbital bleeds were performed every 2 weeks to assess absolute DNTs/mm3. We found rapamycin reduced DNTS to a greater degree than MMF; however, the degree was not statistically significant (S2B) Bars represent mean splenic area (S2A) or mean DNTs (S2B) from mice at each timepoint and error bars represent SEM. p values depict comparisons of rapamycin and MMF treatment by two-tailed t-test.
|
|
